On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi®) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
The risk of dying from cancer has steadily declined in the United States over the past few decades, but Black individuals assigned female at birth still have some of the lowest survival rates. Although Black females are less likely to be diagnosed with cancer than White females, they are they more likely to die from it within five years, according to the National Cancer Institute. The disparity is particularly stark for breast cancer, which kills Black females at a 40% higher rate than White females, even though their rate of diagnosis is 4% lower.
On June 13, 2024, the U.S. Food and Drug Administration granted accelerated approval to repotrectinib (Augtyro™) for adult and pediatric patients aged 12 and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
Oncology nurses are frontrunners in identifying and managing symptoms experienced by people with cancer. From communication approaches and apps to integrative interventions, today’s tools can help nurses more efficiently assess and address side effects, thereby improving patient care.
On June 12, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo®) for adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer that requires systemic therapy but is refractory to radioactive iodine (RAI), if RAI is appropriate.
Implementing a standard guideline for nursing management of patients receiving new U.S. Food and Drug Administration–approved chemotherapy, immunotherapy, and biotherapy decreased 1:1 patient–nursing hours by nearly 65% and saved more than $100,000 per year at one health system in south Florida, a team of nursing leaders reported in a poster presentation at the 49th annual ONS Congress® in April 2024.
More than 40% of patients receiving antibody-drug conjugates (ADCs) will experience ocular toxicities during treatment, ONS members Caroline Clark, MSN, APRN, OCN®, AGCNS, EBP-C, and Ikuko Komo, MSN, CNS, NP, AOCNS®, AOCNP®, reported in an article in the April 2024 issue of the Clinical Journal of Oncology Nursing.
Do you remember the pride you felt when you first put “RN” after your name? Your credentials represent your hard work and dedication. As you add to your education and training, listing your credentials in a standard order ensures they are as meaningful to others as they are to you.
On June 5, 2024, the U.S. Food and Drug Administration (FDA) announced that HomeoCare Laboratories Inc. is voluntarily recalling two batches of StellaLife oral care products to the consumer level because of the presence of microbial contamination.
On June 6, 2024, the U.S. Food and Drug Administration (FDA) approved imetelstat (Rytelo™), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks that has not responded to, has lost response to, or is ineligible for erythropoiesis-stimulating agents.